Clinical trials: Heart Transplant Recipients
Ischemia Reperfusion Injury, Heart Transplantation
Role of Intraoperative Thymoglobulin in Decreasing Ischemia-Reperfusion Injury in Pediatric Heart Transplant Recipients
The restoration of normal blood flow following a period of ischemia may result in ischemia / reperfusion injury (I/RI), which is characterized by inflammation and oxidative damage to tissues.
- Trial name
- NCT00709293
- Testing
- Anti-Thymocyte Globulin, Normal Saline
- Where
- United States
- Sponsor
- University of California, Los Angeles
Heart Transplantation, Acute Renal Failure
Metabolic Pattern of Cyclosporine A and Acute Renal Failure
Following heart transplantation many patients develop acute renal failure in the early posttransplant phase and some are in need of renal replacement therapy for shorter or longer time.
- Trial name
- NCT00264355
- Testing
- cyclosporine A
- Where
- Norway
- Volunteers
- 30 people
- Sponsor
- University of Oslo School of Pharmacy
Pediatric ALL, Transplant; Failure, Heart
HIIT in Pediatric Heart Transplant Recipients (MedBIKE™)
Heart transplantation is the long-term treatment for children and adults with advanced heart failure. Post-transplant outcomes have improved over time, such that 50% of pediatric heart transplant recipients (HTR) remain alive…
- Trial name
- NCT05451979
- Testing
- MedBIKE HIIT
- Where
- Canada
- Volunteers
- 10 people
- Sponsor
- University of Alberta
Diabetes Mellitus, Heart Failure
Diabetes and Lipid Accumulationand Heart Transplant
Idiopathic dilated cardiomyopathy (IDC) is defined by the presence of left ventricular systolic dysfunction in the absence of an abnormal loading condition or significant coronary artery disease.
- Trial name
- DCM-AHEAD (NCT03546062)
- Testing
- patients treated by HTx
- Where
- 2 sites in Italy
- Volunteers
- 177 people
- Sponsor
- University of Campania Luigi Vanvitelli
Cardiac Surgery, Cardiopulmonary Bypass
REnal TRansplant Outcomes After CARdiac Surgery (RETROCAR)
In this retrospective study, the authors assess long term renal outcome in renal transplant recipients after cardiac surgery with cardiopulmonary bypass, and research factors associated with poor long term renal outcome.
- Conditions
- Cardiac Surgery, Cardiopulmonary Bypass, Renal Transplant Recipient
- Trial name
- RETROCAR (NCT04979754)
- Testing
- standard of care
- Where
- France
- Volunteers
- 93 people
- Sponsor
- University Hospital, Bordeaux
Cardiac Transplant Disorder
Study on Heart Rate Variability in Cardiac Transplant Recipients With Exercise and After Exercise Training
The purpose of the study was to investigate the changes on heart rate variability, exercise capacity, activities of daily living, and quality of life after aerobic exercise training in cardiac transplant recipients.
- Trial name
- NCT01760538
- Testing
- Exercise training, usual care
- Where
- Taiwan
- Volunteers
- 30 people
- Sponsor
- National Taiwan University Hospital
Cardiac Transplant
Cytokine Profiling Post-Heart Transplant
Measurement of cytokine levels in post-cardiac transplant patients with unexplained graft dysfunction.
- Trial name
- NCT01643564
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- University of Minnesota
Renal Transplantation, Heart Transplantation
Intracellular and Renal/Myocardial Tissue Concentrations of Cyclosporine A (CsA) and Rejection Frequency Following Transplantation
The primary objective is to investigate intralymphocyte concentrations of CsA in renal and heart transplant recipients to elucidate the association between the intracellular concentration and efficacy (rejection episodes and…
- Trial name
- NCT00139009
- Testing
- Cyclosporine A
- Where
- Norway
- Volunteers
- 30 people
- Sponsor
- University of Oslo School of Pharmacy
End-stage Renal Disease
A Study of Thymoglobuline® Induction Therapy in Adult Recipients of Donated After Cardiac Death Kidney Transplant
Primary Objective: To investigate the efficacy of the standard dose of Thymoglobuline® induction therapy for preventing acute rejection (AR) after transplantation among recipients of Donated after Cardiac Death (DCD) kidney…
- Trial name
- START-DCD (NCT03099122)
- Testing
- Rabbit Anti-thymocyte Immunoglobulin, Tacrolimus, Methylprednisolone
- Where
- China
- Volunteers
- 115 people
- Sponsor
- Sanofi
Diabetes Mellitus Nos New Onset, Hypertrophy, Left Ventricular
New-onset Diabetes and Left Ventricular Hypertrophy in Renal Transplantation
New-onset diabetes (NODAT) after solid organ transplantation is an important clinical challenge associated to increased risk of cardiovascular (CV) events.
- Conditions
- Diabetes Mellitus Nos New Onset, Hypertrophy, Left Ventricular, Vascular Stiffness
- Trial name
- NCT01976689
- Where
- Turkey (Türkiye)
- Volunteers
- 159 people
- Sponsor
- Baskent University
Kidney Dysfunction, Heart Transplantation
Shift to Everolimus (RAD) Kidney Sparing Study
The purpose of this study is to verify if the combination of Everolimus with a very low dose of cyclosporine is more effective than the combination of mycophenolate mofetil with low-dose of cyclosporine in reducing the…
- Trial name
- NCT00420537
- Testing
- cyclosporine, Mycophenolate mofetil, Everolimus
- Where
- Italy
- Volunteers
- 34 people
- Sponsor
- University of Bologna
Hepatitis C, Kidney Transplant; Complications
A Study to Evaluate Preemptive Therapy in Hepatitis C (HCV) Organ Transplant Recipients
This study is being done to determine the effectiveness of using a combination of two different drugs in preventing the transmission of HCV from a HCV positive donor to a HCV negative solid organ recipient.
- Conditions
- Hepatitis C, Kidney Transplant; Complications, Heart Transplant Infection
- Trial name
- NCT04508907
- Testing
- Mavyret
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Mayo Clinic
Nonadherence, Tacrolimus
Improving Medication-taking After Liver Transplant
The specific aim is to pilot-test our developed intervention manual's ability to improve patients' adherence to medications and medical outcomes (rejection rate, liver enzyme levels) in participating centers.
- Conditions
- Nonadherence, Tacrolimus, Pediatric Liver Transplant Recipients
- Trial name
- I-AM (NCT01960322)
- Testing
- Telemetric
- Where
- 3 sites in United States
- Volunteers
- 7 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Heart Transplant
Pharmacokinetics of Immunosuppressive Drugs in Heart Transplant Patients
The main objective is to develop pharmacokinetic methods for individual dose adjustment of the global immunosuppressive treatment (cyclosporine, tacrolimus, mycophenolate mofetil and everolimus, taking into account the…
- Trial name
- PIGREC (NCT00812786)
- Testing
- cyclosporine, tacrolimus, mycophenolate mofetil and everolimus (immunosuppressive drugs)
- Where
- 12 sites in France
- Volunteers
- 42 people
- Sponsor
- University Hospital, Limoges
Heart Transplant Recipient
HEART-BC: Heart Transplant Evaluation Using Advanced Rejection Monitoring Tools - British Columbia
Evaluate whether integration of HeartCare (AlloMap + AlloSure) into routine post-transplant surveillance reduces the number of invasive endomyocardial biopsies (EMBx) in the first year post-transplant
- Trial name
- HEART-BC (NCT07819292)
- Volunteers
- 30 people
- Sponsor
- Cardiology Research UBC
Pediatric Heart Transplant Recipients, Pediatric Cardiac Transplantation
Novel Mobile Device Application to Improve Adherence
The purpose of this study is to collect and compare information on how and when adolescent heart transplant recipients take their prescribed medication.
- Conditions
- Pediatric Heart Transplant Recipients, Pediatric Cardiac Transplantation, Pediatric Heart Transplantation
- Trial name
- NCT02904278
- Testing
- Teen Pocket PATH® Mobile Application, Control Group: Standard of Care
- Where
- 8 sites in United States
- Volunteers
- 26 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Artificial Intelligence (AI), Hepatocellular Carcinoma (HCC)
Use of Machine-learning Algorithms, Biomarkers and Measures of Quality of Life to Personalize Medical Management of Liver and Heart Transplant Recipients
This is an observational, low risk tissue based, non-pharmacological, retrospective-prospective study for adults heart and liver transplant patients, related to IRCCS Azienda Ospedaliero-Universitaria di Bologna (IRCCS AOUBO).
- Conditions
- Artificial Intelligence (AI), Hepatocellular Carcinoma (HCC), Heart Transplantation, Liver Transplantation
- Trial name
- DARE (NCT06774768)
- Where
- 2 sites in Italy
- Volunteers
- 1,000 people
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
Graft Rejection
Safety/Efficacy of Everolimus and Neoral® in Adult Cardiac Transplant Patients With Established Allograft Vasculopathy
Everolimus is an immunosuppressive drug that is being studied for preventing acute rejection that can happen after heart transplantation. It is usually used in combination with other immunosuppressive drugs such as cyclosporine.
- Trial name
- NCT00097968
- Testing
- everolimus
- Where
- 6 sites in United States
- Sponsor
- Novartis Pharmaceuticals
Heart Transplantation
A Study Investigating the Renal Tolerability, Efficacy, and Safety of a CNI-free Versus a Standard Regimen in de Novo Heart Transplant (HTx) Recipients
This study will assess whether a calcineurin inhibitor (CNI)-free regimen with everolimus and mycophenolic acid is associated with a better renal outcome as compared to the standard regimen containing cyclosporine A (which…
- Trial name
- MANDELA (NCT00862979)
- Testing
- Everolimus (EVR), cyclosporine A (CyA), tacrolimus (TAC)
- Where
- 9 sites in Germany
- Volunteers
- 162 people
- Sponsor
- Novartis Pharmaceuticals